| Identification | Back Directory | [Name]
Urapidil hydrochloride | [CAS]
64887-14-5 | [Synonyms]
URAPIDIL HCL
URAPIDIL HYDROCHLORIDE
URAPIDIL HYDROCHLORIDE A1 ADRENOCEPTOR A NTAG
6[[3-[4-(O-METHOXYPHENYL)-1-PIPERAZINYL]PROPYL]AMINO]-1,3-DIMETHYLURACIL HYDROCHLORIDE
6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil hydrochloride
6-[[3-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]PROPYL]AMINO]-1,3-DIMETHYL-2,4(1H,3H)-PYRIMIDINEDIONE
6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione hydrochloride
6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethyl-pyrimidine-2,4-dione hydrochloride
6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethyl-pyrimidine-2,4-quinone hydrochloride
6-[[3-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]PROPYL]AMINO]-1,3-DIMETHYL-2,4(1H,3H)-PYRIMIDINEDIONE HYDROCHLORIDE
6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione,hydrochloride (1:1) | [EINECS(EC#)]
636-348-0 | [Molecular Formula]
C20H30ClN5O3 | [MDL Number]
MFCD00078601 | [MOL File]
64887-14-5.mol | [Molecular Weight]
423.94 |
| Chemical Properties | Back Directory | [Appearance]
White to Off-White Crystalline Powder | [Melting point ]
156-1580C | [storage temp. ]
Desiccate at RT | [solubility ]
H2O: soluble
| [form ]
solid
| [color ]
white
| [Water Solubility ]
Soluble to 50 mM in water | [InChI]
InChI=1S/C20H29N5O3.ClH/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3;/h4-5,7-8,15,21H,6,9-14H2,1-3H3;1H | [InChIKey]
KTMLZVUAXJERAT-UHFFFAOYSA-N | [SMILES]
O(C1C=CC=CC=1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1)C.Cl |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Crystalline Powder | [Uses]
a1-Adrenergic antagonist; derivative of Uracil. Antihypertensive | [Uses]
Antihypertensive;Serotonergic receptor agonist | [Uses]
α1-Adrenergic antagonist; derivative of Uracil (U801000). Antihypertensive. | [Biological Activity]
α 1 -adrenoceptor antagonist and 5-HT 1A receptor agonist (pIC 50 values are 6.13 and 6.4 respectively). Clinically used hypotensive agent. | [Description]
Urapidil(64887-14-5) is an antagonist of α1-adrenergic receptors (α1-ARs) and a partial agonist of the serotonin (5-HT) receptor subtype 5-HT1A.1,2 It selectively binds to α1- over α2-ARs (IC50s = 0.74 and 42 μM, respectively) and to 5-HT1A over 5-HT1B and 5-HT2 receptors (IC50s = 0.4, 20.4, and >10 μM, respectively) in rat cortex.1 Urapidil inhibits cAMP accumulation induced by forskolin in calf hippocampus as a functional model for 5-HT1A receptors (EC50 = 390 nM).3 It is also a β1-AR antagonist that inhibits the positive chronotropic response induced by isoproterenol (Item No. 15592) in isolated rat atria (pA2 = 6.05).4 Urapidil (1 μmol/kg, i.v.) lowers mean arterial pressure (MAP) in anesthetized cats, an effect that is reduced by central administration of the 5-HT1A receptor antagonist spiroxatrine.5
| [Side effects]
Side effects that may occur during treatment with uradil antihypertension include dizziness, fatigue, nausea, and light-headedness effects. The increases in systolic blood pressure heart rate caused by three progressive work loads bicycle exercise were not affected during urapidil, A slight reduction in forced expiratory volume was observed in some patients during treatment with beta-blocker. There was no case orthostatic hypotension during urapidil administration, despite its alpha1-blocking action. Side-effects were rare negligible[1]. | [References]
[1] G LEONETTI. Comparison of the antihypertensive effect of urapidil and metoprolol in hypertension.[J]. European Journal of Clinical Pharmacology, 1986, 30 6: 637-640. DOI:10.1007/BF00608208. |
|
|